Every 10-Q that Kiora Pharmaceuticals, Inc. (KPRX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow KPRX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full KPRX filings page.
Kiora Pharmaceuticals, a clinical-stage ophthalmic company, reported a net loss of $2,079,010 for the quarter and $4,496,994 for the six months ended June 30, 2026. Quarterly operating expenses were $2.2M, including $2.1M of research and development, partially offset by $1.3M of collaboration credits from the KIO‑301 partnership.
Cash, cash equivalents and restricted cash totaled $7.1M and short-term investments $9.8M as of June 30, 2026, with total assets of $23.8M and stockholders’ equity of $16.9M. Management states that, based on these cash resources, it anticipates funding planned operations into late 2028 and does not currently anticipate an immediate need to raise additional capital.
The pipeline centers on KIO‑301, a potential vision-restoring small-molecule photoswitch for degenerative retinal diseases partnered with Théa Open Innovation, and KIO‑104, an intravitreal DHODH inhibitor in Phase 2 for retinal inflammation. Under the Théa license, all KIO‑301 research and development costs are reimbursed.
Kiora Pharmaceuticals, Inc. reported a net loss of $2.4 million for the three months ended March 31, 2026, compared with $2.2 million a year earlier, as it continues investing in ophthalmic drug development.
Total operating expenses were $2.5 million, including $1.6 million in general and administrative costs and $2.1 million in research and development, partly offset by $1.2 million of collaboration credits tied to the KIO‑301 program. Other income, mainly interest, added $0.1 million.
At March 31, 2026, Kiora held $11.0 million in cash and cash equivalents and $2.9 million in short‑term investments, with total assets of $21.2 million and stockholders’ equity of $13.9 million. Management states that, including $5 million raised in an April 2026 private placement and reimbursement of all KIO‑301 expenses by partner Théa Open Innovation, current resources are expected to fund planned operations into late 2028.
Kiora Pharmaceuticals (KPRX) filed its Q3 2025 Form 10‑Q, showing a small quarterly net income of $26,806, driven by lower operating expenses from collaboration credits and a reduction in contingent consideration fair value. For the nine months, the company recorded a net loss of $4,318,633.
Liquidity remained solid with Cash and Cash Equivalents of $5,508,899 and Short‑Term Investments of $13,866,546. Management states these resources are sufficient to fund planned operations into late 2027. Total assets were $29,863,454 and total liabilities were $7,452,712.
Operating expenses in the quarter benefited from Collaboration Credits of $(1,658,248) and a Change in Fair Value of Contingent Consideration of $(1,721,033), offsetting R&D and G&A. The balance sheet includes Deferred Collaboration Revenue of $1,250,000 tied to an option agreement with Senju.
The company highlighted its TOI license executed in 2024 and ongoing ABACUS‑2 activities. Common shares outstanding were 3,433,491 as of September 30, 2025, and 3,677,935 as of November 5, 2025.
Kiora Pharmaceuticals (KPRX) Q2-25 10-Q highlights:
- No revenue this quarter; prior-year period had $20k and $16.0 million YTD license revenue.
- Operating expenses fell 7% YoY to $2.4 million as higher R&D (+26%) was offset by larger collaboration credits.
- Net loss narrowed slightly to $2.2 million (-$0.54/sh); six-month loss $4.3 million.
- Cash & equivalents $1.0 million; short-term investments $19.6 million; total current assets $24.7 million vs $29.7 million at YE-24. Operating cash burn first half $6.5 million.
- Deferred $1.25 million option fee from Senju for Asian rights to KIO-301; potential total deal value up to $110.8 million.
- Contingent consideration liability $4.6 million.
- Management projects existing funds will finance operations into late-2027.
- 3.43 million shares outstanding; warrant exercises added 0.39 million shares YTD.
Liquidity remains solid, but near-term value hinges on clinical progress and additional partnering.